🇺🇸 FDA
Patent

US 10881646

Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers

granted A61KA61K31/4439A61K31/506

Quick answer

US patent 10881646 (Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers) held by Biomed Valley Discoveries, Inc. expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Biomed Valley Discoveries, Inc.
Grant date
Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/4439, A61K31/506, A61K31/519, A61K45/06